
Mark J Truty MD MSc, FACS
Hepatobiliary Surgery, Pancreas, Surgical Oncology (Other than Breast)
Professor of Surgery. Chair - Division of Hepatobiliary and Pancreatic Surgery. Mayo Clinic Rochester
Join to View Full Profile
200 1st St SWRochester, MN 55905
Phone+1 507-284-2166
Fax+1 507-284-5196
Dr. Truty is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Surgical Oncology - Expertise in Pancreatic Cancer, Liver Cancer, Bile Duct Tumors, Gallbladder Cancer, Carcinoid and Neuroendocrine Tumors, Gastric Cancer, Sarcomas, and Intestinal Cancers. Specializing in advanced cancers (deemed unresectable/inoperable elsewhere). Willing to provide free-of-charge 2nd opinions and records review so patients can get definitive and honest answers on the appropriate treatment of their tumors.
Education & Training
- University of Texas M D Anderson Cancer CenterFellowship, Complex General Surgical Oncology, 2009 - 2012
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Surgery, 2002 - 2009
- Chicago Medical SchoolMSc, Pathology, 1999 - 2002
- Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2002
- Chicago Medical SchoolMSc, Physiology, 1998 - 1999
- University of ChicagoBA, Biological Sciences, 1991 - 1995
Certifications & Licensure
- MN State Medical License 2003 - 2025
- TX State Medical License 2009 - 2013
- American Board of Surgery Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Publications & Presentations
PubMed
- Long-Term Reoperation Rates Following Pancreatoduodenectomy for Pancreatic Adenocarcinoma.Chi Zhang, Lauren Lu, Kristine Hanson, Ahmer Sultan, Patrick Starlinger
The American Surgeon. 2025-04-01 - Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study.Jennifer L Leiting, Roberto Alva-Ruiz, Jennifer A Yonkus, Amro M Abdelrahman, Isaac T Lynch
Annals of Surgical Oncology. 2025-03-11 - Alternative lengthening of telomeres and Ki-67 proliferation index provide complementary information on recurrence risk after resection of pancreatic neuroendocrine tu...Hallbera Gudmundsdottir, Rondell P Graham, Patricia T Greipp, Elizabeth B Habermann, Ryan A Knudson
Journal of Neuroendocrinology. 2025-02-13
Authored Content
- Indications and Perioperative Outcomes for Pancreatectomy with Arterial ResectionMay 2018
Press Mentions
- Measurement of Mutant KRAS ctDNA Predicts Pancreatic Cancer OutcomesMarch 26th, 2025
- Measurement of Mutant KRAS ctDNA Predicts Pancreatic Cancer OutcomesMarch 26th, 2025
- Genetic Mutation Predicts Pancreatic Cancer Metastasis and SurvivalMarch 19th, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: